SynthesisInternational journal of molecular sciences2025
A Systematic Review of ABCB1 Polymorphisms and Antiseizure Medication Resistance: Insights from Effect Size and Study Power Analysis.
Synthesis in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Genetic variants associated with clinical characteristics and atopies in eosinophilic esophagitis.The journal of allergy and clinical immunology. Global · 2026Article
- Pharmacogenomics in epilepsy care across Asia.Epilepsia · 2026Review
- Investigating the Impact of ABCB1 3435C>T (rs1045642) Variant on Severity and Cognitive Decline in Egyptian Alzheimer's Disease Patients.Molecular neurobiology · 2026Article
- Association ofFrontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most investigated ABCB1 single-nucleotide polymorphisms (SNPs) related to antiseizure medication resistance are rs1045642 (c.3435C>T, p.Ile1145=), rs2032582 (c.2677G>T/A, p.Ala893Ser/Thr), and rs1128503 (c.1236C>T, p.Gly412=). We conducted a literature review to evaluate the genotype frequencies of rs1045642, rs2032582, and rs1128503 SNPs in different ancestries among the drug-resistant and drug-responsive epilepsy groups. Furthermore, we performed effect size and study power analyses and determined the expected sample size to reach a study power of 0.8 for each conducted research. High and very high statistical power for the rs1045642, rs2032582, and rs1128503 polymorphisms was achieved in 58.0, 60.7, and 31.8% of the studies, respectively. The effect sizes (ES) of rs1045642, rs2032582, and rs1128503 ranged from 0.03-1.04, 0.06-0.92, and 0.04-0.64, respectively. The required sample sizes for rs1045642, rs2032582, and rs1128503 ranged from 9-13,000, 12-2600, and 24-5700 participants, respectively. None of the polymorphisms showed a statistically significant association with antiseizure medication resistance in the forest plots. Our analysis provides valuable guidance for future genetic association studies in the field of drug-resistant epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.